Mga Batayang Estadistika
| CIK | 1479615 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Silence Therapeutics plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Silence Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales 001-39487 Not Applicable (State or other jurisdiction of incorporatio |
|
| August 7, 2025 |
Amended and Restated Articles of Association Exhibit 3.1 Company No. 02992058 The Companies Act 2006 Articles of Association of Silence Therapeutics plc Adopted by the Company on 26 June 2025 Public Company Limited by Shares (Incorporated on 18 November 1994) COOLEY (UK) LLP, 22 BISHOPSGATE, LONDON EC2N 4BQ, UK T: +44 (0) 20 7583 4055 F: +44 (0) 20 7785 9355 WWW.COOLEY.COM CONTENTS ARTICLE PAGE 1. Exclusion of Model Articles and Table A 1 2. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Silence Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales 001-39487 Not Applicable (State or other jurisdiction of incorporation |
|
| August 7, 2025 |
EX-99.1 Exhibit 99.1 Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights • Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV • SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025 7 August 2025 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39487 Silence Therapeutics |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Silence Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales 001-39487 Not Applicable (State or other jurisdiction of incorporation) |
|
| May 16, 2025 |
Table of Contents SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 8, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Silence Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales 001-39487 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39487 Silence Therapeutics |
|
| May 8, 2025 |
EX-99.1 Exhibit 99.1 Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Company further extends cash guidance into 2028 8 May 2025 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarte |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Silence Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales 001-39487 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| May 6, 2025 |
Exhibit 99.1 Silence Therapeutics Welcomes Tim McInerney to Board of Directors Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors 6 May 2025 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short inte |
|
| May 6, 2025 |
Table of Contents SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 30, 2025 |
Employment Agreement, dated as of March 5, 2022, by and between the Registrant and Craig Tooman Exhibit 10.13 Dear Craig: This letter agreement (the “Agreement”) amends, fully restates and sets forth the terms and conditions of your employment with Silence Therapeutics Plc (the “Company”) effective February 21, 2022. 1. Duties and Responsibilities (a) You will serve as President and Chief Executive Officer of the Company. In this capacity, you will have the duties, responsibilities and autho |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| April 30, 2025 |
Employment Agreement, dated as of March 9, 2023, by and between the Registrant and Steven Romano Exhibit 10.15 Dear Steve: This letter agreement (the “Agreement”) sets forth the terms and conditions of your employment with Silence Therapeutics Plc (the “Company”) effective April 1, 2023. 1. Duties and Responsibilities (a) You will serve as Interim Chief Medical Officer (CMO) from April 1, 2023. In this capacity, you will report to Head of R&D (currently Giles Campion) and perform such executi |
|
| April 30, 2025 |
Employment Agreement, dated as of March 8, 2022, by and between the Registrant and Rhonda Hellums Exhibit 10.14 Dear Rhonda: This letter agreement (the “Agreement”) amends, fully restates and sets forth the terms and conditions of your employment with Silence Therapeutics Plc (the “Company”) effective February 21, 2022. 1. Duties and Responsibilities (a) You will serve as Chief Financial Officer of the Company. In this capacity, you will have the duties, responsibilities and authority customar |
|
| February 27, 2025 |
Exhibit 99.1 Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update The Company’s cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT 27 February 2025 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interferin |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Silence Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary Shares, nominal value £0. |
|
| February 27, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Silence Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales 001-39487 Not Applicable (State or other jurisdiction of incorporat |
|
| February 27, 2025 |
Exhibit 19.1 Silence Therapeutics plc Insider Trading Policy Approved by the Board of Directors December 13, 2024 Introduction During the course of your relationship with Silence Therapeutics plc (the “Company”), you may receive material information that is not yet publicly available (“material nonpublic information”) about the Company or other publicly traded companies with which the Company has |
|
| February 27, 2025 |
Exhibit 99.2 Full Year 2024 Results February 27, 2025 Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39487 Silence Therape |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Description of Share Capital and Articles of Association Exhibit 4.3 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, or the Articles, and relevant provisions of the U.K. Companies Act 2006, or the Companies Act. The summary below contains only material information concerning our share ca |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 Silence Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-39487 Not Applicable (State or other jurisdiction of incorporatio |
|
| December 20, 2024 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Ordinary Shares of Silence Therapeutics plc shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. |
|
| December 20, 2024 |
Schedule 1 Transactions in ADSs During the Past Sixty Days EXHIBIT B Schedule 1 Transactions in ADSs During the Past Sixty Days Date Nature of the Transaction Reporting Person Amount of Securities Purchased/Sold Price 12/18/24 Purchase Richard Griffiths 30,000 $ 6. |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| December 9, 2024 |
Exhibit 99.1 Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting New divesiran data continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients Silence also announces first subject dosed in Phase 2 study of divesiran in PV patients Company reinforces commitm |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| November 18, 2024 |
Exhibit 99.1 Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose Represents first study to report time-averaged Lp(a) results to further evaluate potential clinical benefits Data simultaneously publishe |
|
| November 14, 2024 |
SLNCF / Silence Therapeutics plc / Lombard Odier Asset Management (USA) Corp Passive Investment SC 13G/A 1 silence13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) * Silence Therapeutics plc (Name of Issuer) Ordinary Shares, par value £0.05 per share (Title of Class of Securities) G8128Y157 (Cusip Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| November 14, 2024 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended Nine months ended Nine months ended September 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 £000s (except per share information) £000s £000s £000s £000s Revenue 1,142 2,798 14,146 23,276 Cost of sales (2,774 ) (1,607 ) (7,625 ) (8,972 ) Gross profit (1,632 ) 1,191 6,521 14,304 |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| November 14, 2024 |
SLNCF / Silence Therapeutics plc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-sln093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Silence Therapeutics plc (Name of Issuer) Ordinary Shares, par value £0.05 per share (Title of Class of Securities) G8128Y157 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) C |
|
| November 12, 2024 |
EX-99.1 2 d831423dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of Silence Therapeutics plc is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchan |
|
| November 12, 2024 |
SC 13G/A 1 d831423dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 3) Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.05 per share (Title of Class of Securities) 82686Q101** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat |
|
| October 22, 2024 |
As filed with the Securities and Exchange Commission on October 22, 2024. Table of Contents As filed with the Securities and Exchange Commission on October 22, 2024. |
|
| October 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Silence Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Ordinary shares, nominal value £0. |
|
| August 15, 2024 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended Six months ended Six months ended June 30, 2024 June 30, 2023 June 30, 2024 June 30, 2023 £000s (except per share information) £000s £000s £000s £000s Revenue 598 9,104 13,004 20,478 Cost of sales (2,638 ) (2,831 ) (4,851 ) (7,365 ) Gross profit (2,040 ) 6,273 8,153 13,113 Research and developmen |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princ |
|
| August 2, 2024 |
SC 13G/A 1 d780589dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.05 per share (Title of Class of Securities) 82686Q101** (CUSIP Number) July 25, 2024 (Date of Event Which Requires Filing of this Statement |
|
| August 2, 2024 |
EX-99.1 2 d780589dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of Silence Therapeutics plc is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchan |
|
| June 27, 2024 |
Exhibit 99.1 Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time 27 June 2024 LONDON, Silen |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princip |
|
| June 27, 2024 |
Exhibit 99.2 Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera June 27, 2024 Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as anticipates, believes, expects, intends, “pl |
|
| June 24, 2024 |
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration Exhibit 99.1 Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration 24 June 2024 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a $2. |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princip |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princip |
|
| June 20, 2024 |
Exhibit 99.1 Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose 20 June 2024 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced a |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| May 16, 2024 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended March 31, 2024 March 31, 2023 £000s (except per share information) £000s £000s Revenue 12,406 11,374 Cost of sales (2,213 ) (4,534 ) Gross profit 10,193 6,840 Research and development costs (9,179 ) (12,539 ) General and administrative expenses (5,170 ) (6,450 ) Operating loss (4,156 ) (12,149 ) |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| May 14, 2024 |
5,714,286 American Depositary Shares Representing 17,142,858 Ordinary Shares Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-279185 PROSPECTUS 5,714,286 American Depositary Shares Representing 17,142,858 Ordinary Shares This prospectus relates to the resale by the selling securityholders identified in this prospectus, or the selling securityholders, of up to 5,714,286 American Depositary Shares, or ADSs, representing 17,142,858 ordinary shares, n |
|
| May 10, 2024 |
May 10, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Silence Therapeutics plc (the “Company”) Registration Statement on Form F-3 Filed: May 7, 2024 File No. 333-279185 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests |
|
| May 8, 2024 |
SILENCE THERAPEUTICS PLC 72 Hammersmith Road London W14 8TH United Kingdom SILENCE THERAPEUTICS PLC 72 Hammersmith Road London W14 8TH United Kingdom May 8, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 7, 2024 |
As filed with the Securities and Exchange Commission on May 7, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 7, 2024 Registration No. |
|
| May 7, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Silence Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity American Depositary Shares (ADSs) 457(c) 5,714,286 $21. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| April 29, 2024 |
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors EX-99.1 Exhibit 99.1 Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors 29 April 2024 LONDON, Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served |
|
| April 29, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pr |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| April 15, 2024 |
Exhibit 99.1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this Document, please take advice from a stockbroker, solicitor, accountant or other independent professional adviser. If you have sold or otherwise transferred all of your holdings of Ordinary Shares, you should immediately forward this Document a |
|
| April 15, 2024 |
Exhibit 99.2 Annual General Meeting of Annual General Meeting of Silence Therapeutics plc Silence Therapeutics plc to be held May 17, 2024 Date: May 17, 2024 See Voting Instruction On Reverse Side. For Holders as of April 4, 2024 Please make your marks like this: x Use pen only ? Ordinary resolutions For Against Abstain . INTERNET TELEPHONE 1. To receive and adopt the accounts for the ?nancial yea |
|
| March 27, 2024 |
SLNCF / Silence Therapeutics plc / Griffiths Richard Ian - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.05 per share (Title of Class of Securities) G8128Y157 (CUSIP Number) Richard Griffiths Floor 1 Liberation Station Esplanade, St Helier, Jersey, JE2 3AS Tel: +44 1534 719 |
|
| March 27, 2024 |
EX-99.A 2 d792279dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Ordinary Shares of Silence Therapeutics plc shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: March 27, 2024 Ora Capital Limited By: /s/ Richard Ian |
|
| March 13, 2024 |
Consent of PricewaterhouseCoopers LLP Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-260265) and Form S-8s (No. 333-248682 and No. 333-273576) of Silence Therapeutics plc of our report dated March 13, 2024 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers LLP Rea |
|
| March 13, 2024 |
Exhibit 99.1 Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) Study met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36 Lipoprotein(a) reduction was consistent with phase 1 results Topline 48-week data expected in 2Q 2024 13 March 2023 LONDON, Silence Therapeutics plc, Nasd |
|
| March 13, 2024 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Exhibit 12.2 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Rhonda Hellums, certify that: 1. I have reviewed this annual report on Form 20-F of Silence Therapeutics plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fa |
|
| March 13, 2024 |
Description of Share Capital and Articles of Association Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, or the Articles, and relevant provisions of the U.K. Companies Act 2006, or the Companies Act. The summary below contains only material information concerning our share ca |
|
| March 13, 2024 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Exhibit 12.1 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, certify that: 1. I have reviewed this annual report on Form 20-F of Silence Therapeutics plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| March 13, 2024 |
Section 1350 Certification of Chief Executive Officer Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, President and Chief Executive Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on F |
|
| March 13, 2024 |
Section 1350 Certification of Chief Financial Officer Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Rhonda Hellums, Chief Financial Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of |
|
| March 13, 2024 |
Silence Therapeutics plc Compensation Clawback Policy Exhibit 97.1 Silence Therapeutics plc Compensation Clawback Policy Adopted November 8, 2023 Purpose The Board of Directors (the “Board”) of Silence Therapeutics plc (the “Company”) has adopted this compensation clawback policy (the “Policy”) which provides for the recoupment of incentive-based compensation in the event of an accounting restatement. This Policy is intended to comply with Section 10 |
|
| March 13, 2024 |
2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Plan Exhibit 4.10 Silence Therapeutics Plc 2023 Equity Incentive Plan With Non-Employee Sub-Plan and CSOP Sub-Plan Adopted by the Board of Directors: 20 March 2023 Approved by the Shareholders: April 27, 2023 1. Table of Contents Page -i- 2. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions t |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| February 23, 2024 |
Exhibit 99.1 Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial 23 February 2024 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| February 14, 2024 |
SLNCF / Silence Therapeutics plc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
SLNCF / Silence Therapeutics plc / Lombard Odier Asset Management (USA) Corp Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2024 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.05 per share (Title of Class of Securities) 82686Q101** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 6, 2024 |
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 2, 2024 by and among Silence Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as |
|
| February 6, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 77 Hammersmith Road London W14 8TH United Kingdom (Address of |
|
| February 6, 2024 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 2, 2024 by and among Silence Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. |
|
| February 6, 2024 |
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement Exhibit 99.3 Silence Therapeutics Announces Oversubscribed $120 Million Private Placement LONDON, February 5, 2024 – Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced an oversubscribed private placement of 5,71 |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| December 1, 2023 |
Exhibit 99.1 Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer 1 December 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| November 14, 2023 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended Nine months ended Nine months ended September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 £000s (except per share information) £000s £000s £000s £000s Revenue 2,798 3,371 23,276 12,736 Cost of sales (1,607 ) (2,394 ) (8,972 ) (7,021 ) Gross profit 1,191 977 14,304 5,715 Rese |
|
| November 1, 2023 |
Exhibit 99.1 Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint 1 November 2023 LONDON, Silence Thera |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| September 1, 2023 |
US82686Q1013 / SILENCE THERAPEUTICS PLC ADR / Artal International S.C.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.05 per share (Title of Class of Securities) 82686Q101** (CUSIP Number) August 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| September 1, 2023 |
EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Ordinary Shares, nominal value £0.05 per share (the “Shares”), of Silence Therapeutics plc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securi |
|
| August 29, 2023 |
Report for the Three and Six Months Ended June 30, 2023 Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended Six months ended Six months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 £000s (except per share information) £000s £000s £000s £000s Revenue 9,104 3,643 20,478 9,365 Cost of sales (2,831 ) (2,352 ) (7,365 ) (4,627 ) Gross profit 6,273 1,291 13,113 4,738 Research and development |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| August 16, 2023 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended Six months ended Six months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 £000s (except per share information) £000s £000s £000s £000s Revenue 9,104 3,643 20,478 9,365 Cost of sales (2,831 ) (2,352 ) (7,365 ) (4,627 ) Gross profit 6,273 1,291 13,113 4,738 Research and development |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princ |
|
| August 14, 2023 |
SLNCF / Silence Therapeutics Plc / Griffiths Richard Ian - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.05 per share (Title of Class of Securities) G8128Y157 (CUSIP Number) Richard Griffiths Floor 1 Liberation Station Esplanade, St Helier, Jersey, JE2 3AS Tel: +44 1534 719761 (Name |
|
| August 1, 2023 |
Amended and Restated Articles of Association Exhibit 4.1 Company No. 02992058 The Companies Act 2006 Articles of Association of Silence Therapeutics plc Adopted by the Company on 1 November 2021 Public Company Limited by Shares (Incorporated on 18 November 1994) Cooley (UK) LLP, 22 Bishopsgate, London EC2n 4bq, UK T: +44 (0) 20 7583 4055 F: +44 (0) 20 7785 9355 www.cooley.com CONTENTS ARTICLE PAGE 1. Exclusion of Model Articles and Table A 1 |
|
| August 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Silence Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary Shares, nominal value £0. |
|
| August 1, 2023 |
As filed with the Securities and Exchange Commission on August 1, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 1, 2023 |
Silence Therapeutics plc 2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan Exhibit 99.1 Silence Therapeutics Plc 2023 Equity Incentive Plan With Non-Employee Sub-Plan and CSOP Sub-Plan Adopted by the Board of Directors: 20 March 2023 Approved by the Shareholders: 27 April 2023 Table of Contents Page 1. PURPOSE 1 2. ELIGIBILITY 1 3. ADMINISTRATION AND DELEGATION. 1 4. SHARES AVAILABLE FOR AWARDS. 2 5. OPTIONS AND SHARE APPRECIATION RIGHTS. 3 6. RESTRICTED SHARES; RESTRICT |
|
| August 1, 2023 |
Silence Therapeutics plc 2018 Long-Term Incentive Plan Exhibit 99.2 Silence Therapeutics plc The Silence Therapeutics plc 2018 Employee Long Term Incentive Plan Board adoption: February 2nd, 2018 Plan expires: February 1st, 2028 Shareholder approval: 23 July 2020 PricewaterhouseCoopers LLP, The Atrium, 1 Harefield Road, Uxbridge, Middlesex, UB8 1EX T: +44 (0) 1895 522 000, F: +44 (0) 1895 522 020, www.pwc.co.uk PricewaterhouseCoopers LLP is a limited |
|
| August 1, 2023 |
Silence Therapeutics plc 2018 Non-Employee Long-Term Incentive Plan Exhibit 99.3 Silence Therapeutics plc The Silence Therapeutics plc 2018 Non-Employee Long Term Incentive Plan Board adoption: 2nd February 2018 Plan expires: 1st February 2028 Shareholder approval: 23 July 2020 PricewaterhouseCoopers LLP, The Atrium, 1 Harefield Road, Uxbridge, Middlesex, UB8 1EX T: +44 (0) 1895 522 000, F: +44 (0) 1895 522 020, www.pwc.co.uk PricewaterhouseCoopers LLP is a limite |
|
| July 11, 2023 |
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration 11 July 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a $4. |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princip |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princip |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| May 16, 2023 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended March 31, 2023 March 31, 2022 £000s (except per share information) '£000s '£000s Revenue 11,374 5,722 Cost of sales (4,534 ) (2,275 ) Gross profit 6,840 3,447 Research and development costs (12,539 ) (7,603 ) General and administrative expenses (6,450 ) (5,766 ) Operating loss (12,149 ) (9,922 ) |
|
| May 4, 2023 |
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration 4 May 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| May 1, 2023 |
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events 1 May 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that it has completed enrollment in the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in subjects with elevated lipoprotein(a) (“Lp(a)”) at high risk of atherosclerotic cardiovascular disease (“ASCVD”) events. |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| March 28, 2023 |
Silence Therapeutics to Buyback siRNA Complement Assets Exhibit 99.2 Silence Therapeutics to Buyback siRNA Complement Assets Deal gives Silence exclusive worldwide rights to two siRNA complement assets 28 March 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today ann |
|
| March 28, 2023 |
Exhibit 99.1 Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development - Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end 28 March 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transformi |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| March 15, 2023 |
Consent of PricewaterhouseCoopers LLP Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-260265) and Form S-8 (No. 333-248682) of Silence Therapeutics plc of our report dated March 15, 2023 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers LLP Reading, United Kingdom |
|
| March 15, 2023 |
Description of American Depositary Shares Exhibit 2.4 DESCRIPTION OF AMERICAN DEPOSITARY SHARES American Depositary Shares The Bank of New York Mellon, as depositary, will register and deliver American Depositary Shares, or ADSs. Each ADS will represent three ordinary shares (or a right to receive three ordinary shares) deposited with The Bank of New York Mellon, acting through an office located in the United Kingdom, as custodian. Each A |
|
| March 15, 2023 |
Section 1350 Certification of Chief Executive Officer Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, President and Chief Executive Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on F |
|
| March 15, 2023 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Exhibit 12.2 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Rhonda Hellums, certify that: 1. I have reviewed this annual report on Form 20-F of Silence Therapeutics plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fa |
|
| March 15, 2023 |
Description of Share Capital and Articles of Association Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, or the Articles, and relevant provisions of the U.K. Companies Act 2006, or the Companies Act. The summary below contains only material information concerning our share ca |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 15, 2023 |
Section 1350 Certification of Chief Financial Officer Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Rhonda Hellums, Chief Financial Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of |
|
| March 15, 2023 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Exhibit 12.1 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, certify that: 1. I have reviewed this annual report on Form 20-F of Silence Therapeutics plc (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact |
|
| March 15, 2023 |
Exhibit 4.7 THE SYMBOL [***] DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE. EXCLUSIVE RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and between Silence Therapeutics PLC and HANSOH (Shanghai) Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company |
|
| February 14, 2023 |
SLNCF / Silence Therapeutics, Plc. / Lombard Odier Asset Management (USA) Corp Passive Investment SC 13G/A 1 13ga1silence.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * Silence Therapeutics plc (Name of Issuer) Ordinary Shares, par value £0.05 per share (Title of Class of Securities) G8128Y157 (Cusip Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| February 14, 2023 |
SLNCF / Silence Therapeutics, Plc. / TCG Crossover GP I, LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 silence213230sc13ga1.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.05 per share (Title of Class of Securities) G8128Y157 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of prin |
|
| January 12, 2023 |
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates Exhibit 99.1 Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates 12 January 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today provided the following SLN360 and SLN124 program updates duri |
|
| November 10, 2022 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended Nine months ended Nine months ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 ?000s (except per share information) '?000s '?000s '?000s '?000s Revenue 3,371 3,156 12,736 9,001 Cost of sales (2,394 ) (2,052 ) (7,021 ) (5,414 ) Gross profit 977 1,104 5,715 3,587 Re |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| November 7, 2022 |
Exhibit 99.1 Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting ? Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period 5 November 2022 Silence Therapeutics plc, Nasdaq: SLN (?Silence? or ?the Company?), an exp |
|
| October 20, 2022 |
SLNCF / Silence Therapeutics, Plc. / Griffiths Richard Ian - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value £0.05 per share (Title of Class of Securities) G8128Y157 (CUSIP Number) Richard Griffiths Floor 1 Liberation Station Esplanade, St Helier, Jersey, JE2 3AS Tel: +44 1534 719761 (Name |
|
| September 29, 2022 |
Exhibit 99.1 Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia 29 September 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (?Silence? or ?the Company?), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medic |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pr |
|
| August 22, 2022 |
SLNCF / Silence Therapeutics, Plc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 19, 2022 |
SLNCF / Silence Therapeutics, Plc. / TCG Crossover Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Silence Therapeutics plc (Name of Issuer) Common Stock, ?0.05 par value (Title of Class of Securities) G8128Y157 (CUSIP Number) August 12, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princ |
|
| August 16, 2022 |
EX-1.1 2 d342872dex11.htm EX-1.1 Exhibit 1.1 SILENCE THERAPEUTICS PLC AMERICAN DEPOSITARY SHARES OF THE COMPANY, EACH REPRESENTING THREE ORDINARY SHARES, NOMINAL VALUE £0.05 PER SHARE UNDERWRITING AGREEMENT August 11, 2022 August 11, 2022 To the Managers named in Schedule I hereto for the Underwriters named in Schedule II hereto Ladies and Gentlemen: Silence Therapeutics plc, a public limited comp |
|
| August 12, 2022 |
5,950,000 American Depositary Shares Representing 17,850,000 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260265 PROSPECTUS SUPPLEMENT (to prospectus dated October 22, 2021) 5,950,000 American Depositary Shares Representing 17,850,000 Ordinary Shares We are offering 5,950,000 American Depositary Shares, or ADSs, representing 17,850,000 ordinary shares, nominal value ?0.05 each, of Silence Therapeutics plc offered by this prospectu |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princ |
|
| August 12, 2022 |
Silence Therapeutics Announces Pricing of Underwritten Offering Exhibit 99.1 Silence Therapeutics Announces Pricing of Underwritten Offering LONDON, August 11, 2022 ? Silence Therapeutics plc (Nasdaq: SLN) (?Silence?), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the pricing of an underwritten offering of 5, |
|
| August 11, 2022 |
EX-99.1 2 sln-ex9916.htm EX-99.1 Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended Six months ended Six months ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 £000s (except per share information) '£000s '£000s '£000s '£000s Revenue 3,643 2,701 9,365 5,845 Cost of sales (2,352 ) (1,825 ) (4,627 ) (3,362 ) Gross profit 1,291 876 4,73 |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princ |
|
| July 20, 2022 |
SLNCF / Silence Therapeutics, Plc. / Griffiths Richard Ian - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value ?0.05 per share (Title of Class of Securities) G8128Y157 (CUSIP Number) Richard Griffiths Floor 1 Liberation Station Esplanade, St Helier, Jersey, JE2 3AS Tel: +44 1534 719761 (Name |
|
| June 15, 2022 |
SLNCF / Silence Therapeutics, Plc. / Griffiths Richard Ian - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Silence Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value ?0.05 per share (Title of Class of Securities) G8128Y157 (CUSIP Number) Richard Griffiths Floor 1 Liberation Station Esplanade, St Helier, Jersey, JE2 3AS Tel: +44 1534 719761 (Name, |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princip |
|
| May 16, 2022 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended March 31, 2022 March 31, 2021 ?000s (except per share information) Revenue 5,722 3,144 Cost of sales (2,275 ) (1,537 ) Gross profit 3,447 1,607 Research and development costs (7,603 ) (7,458 ) General and administrative expenses (5,766 ) (3,749 ) Other gains - net - 259 Operating loss (9,922 ) (9 |
|
| May 16, 2022 |
Explanatory notes to the Notice of Annual General Meeting Exhibit 99.1 Silence Therapeutics plc Notice of Annual General Meeting Notice of Annual General Meeting THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action to take, you should consult your stockbroker, solicitor, accountant or other appropriate independent professional adviser authorised under the Financial Services and Markets Act 2000. If y |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| April 25, 2022 |
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration EX-99.1 2 sln-ex9916.htm EX-99.1 Exhibit 99.1 Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration 25 April 2022 LONDON, Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced t |
|
| April 4, 2022 |
Exhibit 99.1 Silence Therapeutics Announces Detailed Results from SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting ? SLN360 reduced Lp(a) ? a key genetic risk factor for heart disease - by up to 98% with reductions of up to 81% persisting at 150 days ? Results were simultaneously published in The Journal of the Amer |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| March 23, 2022 |
Exhibit 99.1 Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501 Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first half of 2022 23 March 2022 LONDON AND DUBLIN, Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering rib |
|
| March 17, 2022 |
Description of Share Capital and Articles of Association Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, or the Articles, and relevant provisions of the U.K. Companies Act 2006, or the Companies Act. The summary below contains only material information concerning our share ca |
|
| March 17, 2022 |
Section 1350 Certification of Chief Financial Officer Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Rhonda Hellums, Chief Financial Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of |
|
| March 17, 2022 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Exhibit 12.1 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, certify that: 1. I have reviewed this annual report on Form 20-F of Silence Therapeutics plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to stat |
|
| March 17, 2022 |
Description of American Depositary Shares EX-2.4 3 sln-ex248.htm EX-2.4 Exhibit 2.4 DESCRIPTION OF AMERICAN DEPOSITARY SHARES American Depositary Shares The Bank of New York Mellon, as depositary, will register and deliver American Depositary Shares, or ADSs. Each ADS will represent three ordinary shares (or a right to receive three ordinary shares) deposited with The Bank of New York Mellon, acting through an office located in the United |
|
| March 17, 2022 |
Section 1350 Certification of Chief Executive Officer Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, President and Chief Executive Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on F |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 17, 2022 |
Consent of PricewaterhouseCoopers LLP Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-260265) and Form S-8 (No. 333-248682) of Silence Therapeutics plc of our report dated March 17, 2022 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers LLP Reading, United Kingdom |
|
| March 17, 2022 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Exhibit 12.2 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Rhonda Hellums, certify that: 1. I have reviewed this annual report on Form 20-F of Silence Therapeutics plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st |
|
| March 17, 2022 |
Exhibit 4.7 THE SYMBOL [***] DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE. EXCLUSIVE RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and between Silence Therapeutics PLC and HANSOH (Shanghai) Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| February 22, 2022 |
Exhibit 99.1 Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer Mark Rothera steps down as President and CEO 21 February 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN (?Silence? or ?the Company?), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (?siRNA?) therapeutics for the treatment of diseases with significant un |
|
| February 14, 2022 |
SLNCF / Silence Therapeutics, Plc. / Griffiths Richard Ian - SC 13G Passive Investment SC 13G 1 d315151dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Silence Therapeutics plc (Name of Issuer) Ordinary Shares, par value £0.05 per share (Title of Class of Securities) G8128Y157 (Cusip Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check th |
|
| February 14, 2022 |
SLNCF / Silence Therapeutics, Plc. / Quested Robert - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2022 |
Exhibit 99.1 Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a) SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360 significantly lowered Lp(a) in a dose-dependent manner up to 98% with reductions of up to 81% persisting at |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| February 7, 2022 |
SLNCF / Silence Therapeutics, Plc. / Mallinckrodt Plc - SC 13G Passive Investment SC 13G 1 d304762dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Silence Therapeutics plc (Name of Issuer) Ordinary shares, nominal va |
|
| February 7, 2022 |
Exhibit 1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with the U. |
|
| December 13, 2021 |
Exhibit 99.1 New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases ? Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and transferrin saturation, strong safety profile and long duration of action ? Data support ongoing studies in patients with thalassemia and myelodysplastic syndrome and a new planned study in |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| November 26, 2021 |
Silence Therapeutics plc: Update on AIM Delisting Exhibit 99.1 Silence Therapeutics plc: Update on AIM Delisting 26 November 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN (?Silence? or ?the Company?), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today provides a further update with respect to t |
|
| November 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| November 16, 2021 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Three months ended Three months ended Nine months ended Nine months ended September 30, 2021 September 30, 2020 September 30, 2021 September 30, 2020 ?000s (except per share information) Revenue 3,156 1,988 9,001 3,134 Cost of sales (2,052 ) (2,331 ) (5,414 ) (2,331 ) Gross profit 1,104 (343 ) 3,587 803 Research and development costs |
|
| November 1, 2021 |
EX-99.1 2 d236728dex991.htm EX-99.1 Exhibit 99.1 Results of General Meeting 1 November 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its general m |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| October 22, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260265 PROSPECTUS SUPPLEMENT (to prospectus dated October 22, 2021) Silence Therapeutics plc Up to $100,000,000 Ordinary Shares (in the Form of American Depositary Shares) We have entered into an Open Market Sale Agreement SM, or sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of American Depositary Sha |
|
| October 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of prin |
|
| October 21, 2021 |
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Exhibit 99.1 Silence Therapeutics Provides mRNAi GOLD? Platform and Pipeline Updates at 2021 R&D Day - Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endogenous hepcidin modulation - SLN360 single-ascending dose study on-track for topline data in Q1?22 ? independent review committee recommends extending follow-up period |
|
| October 20, 2021 |
October 20, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jane Park Re: Silence Therapeutics plc (the ?Company?) Registration Statement on Form F-3 Filed: October 15, 2021 File No. 333-260265 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests th |
|
| October 18, 2021 |
As filed with the Securities and Exchange Commission on October 18, 2021 Table of Contents As filed with the Securities and Exchange Commission on October 18, 2021 Registration No. |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| October 15, 2021 |
As filed with the Securities and Exchange Commission on October 15, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 15, 2021. |
|
| October 15, 2021 |
Exhibit 99.4 THIS DOCUMENT AND THE ENCLOSED DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this Document, please take advice from a stockbroker, solicitor, accountant or other independent professional adviser. If you have sold or otherwise transferred all of your Ordinary Shares, please send this Document, toge |
|
| October 15, 2021 |
APPENDIX A PART A ISSUANCE PROCESS Exhibit 99.5 FREQUENTLY ASKED QUESTIONS 1. DO I NEED TO SELL MY AIM-QUOTED ORDINARY SHARES OR MUST I DEPOSIT THEM FOR DELIVERY OF NASDAQ-LISTED ADSs? Holders of Silence Ordinary Shares now have three options: (a) You may choose to deposit your Ordinary Shares for delivery of ADSs tradeable on Nasdaq If your investment is currently held in CREST and managed by a broker, your broker will be able to |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of prin |
|
| October 15, 2021 |
As filed with the Securities and Exchange Commission on October 15, 2021 As filed with the Securities and Exchange Commission on October 15, 2021 Registration No. |
|
| October 15, 2021 |
Exhibit 99.1 Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be held on 1 November 2021 15 October 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN (?Silence? or ?the Company?), a leader in the discovery, development and delivery of novel s |
|
| October 15, 2021 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM October 15, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Silence Therapeutics plc, a public limited company incorporated under the laws of England and Wales with registered number 02992058 (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferie |
|
| October 15, 2021 |
Exhibit 99.2 Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence?s mRNAi GOLD? Platform Hansoh will make a $16 million upfront cash payment and Silence has the potential to receive up to $1.3 billion in milestones Silence gains exclusive rights to two targets in all territories except the China region; Hansoh has rights to those two targets in t |
|
| October 15, 2021 |
Half-Year Report for the Six Months Ended June 30, 2021 Exhibit 99.1 Condensed consolidated income statement (unaudited) Six months ended June 30, 2021 June 30, 2020 ?000s (except per share information) Revenue 5,845 1,146 Cost of sales (3,362) ? Gross profit 2,483 1,146 Research and development costs (15,625) (10,179) Administrative expenses (9,126) (5,160) Other (losses)/gains?net ? ? Operating loss (22,268) (14,193) Finance and other expenses (312) |
|
| October 15, 2021 |
Exhibit 99.3 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (?UK MAR?). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. NOT FOR RELEASE, PUBLICATION OR DIST |
|
| August 12, 2021 |
Exhibit 99.1 Condensed consolidated income statement (unaudited) Six months ended Year ended June 30, 2021 June 30, 2020 December 31, 2020 ?000s (except per share information) Revenue 5,845 1,146 5,479 Cost of sales (3,362 ) - (3,762 ) Gross profit 2,483 1,146 1,717 Research and development costs (15,625 ) (10,179 ) (20,209 ) Administrative expenses (9,126 ) (5,160 ) (13,983 ) Other (losses)/gains |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princ |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princ |
|
| August 12, 2021 |
Silence Therapeutics Reports Half-Year 2021 Results Exhibit 99.1 Silence Therapeutics Reports Half-Year 2021 Results – Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a) – Silence to host R&D Day in New York City on October 21, 2021 August 12, 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, d |
|
| June 15, 2021 |
Results of Annual General Meeting Exhibit 99.1 Results of Annual General Meeting 15 June 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its Annual General Meeting held today, 15 Ju |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princip |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princip |
|
| June 7, 2021 |
EX-99.1 2 sln-ex9916.htm EX-99.1 Exhibit 99.1 Silence Therapeutics to Present Data Highlighting Broad Therapeutic Potential for SLN124 at the European Hematology Association (EHA) 2021 Virtual Congress – Preclinical data at EHA support recently reported positive topline clinical data for SLN124 in healthy volunteers – SLN124 is being evaluated in the ongoing GEMINI II phase 1 study in patients wit |
|
| May 25, 2021 |
EX-99.1 2 d173521dex991.htm EX-99.1 Exhibit 99.1 Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration – Companies on-track to initiate work on five targets within the first three years of the collaboration 25 May 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| May 19, 2021 |
May 2021 Corporate Presentation Silence Therapeutics Exhibit 99.2 Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be r |
|
| May 19, 2021 |
Exhibit 99.1 Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers ? Data showed SLN124, an siRNA which targets TMPRSS6, was safe and effective in reducing plasma iron levels and had a long duration of action ? Data support ongoing phase 1 study of SLN124 in patients with thalassemia and myelodysplastic syndrome (MDS) ? First clinical data from Sile |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| May 7, 2021 |
Notice of Annual General Meeting Exhibit 99.1 Notice of Annual General Meeting 7 May 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that this year's Annual General Meeting ("AGM") of the |
|
| May 7, 2021 |
Exhibit 99.2 Silence Therapeutics plc Notice of Annual General Meeting 01 Notice of Annual General Meeting THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action to take, you should consult your stockbroker, solicitor, accountant or other appropriate independent professional advis |
|
| May 7, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principa |
|
| April 29, 2021 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Exhibit 12.1 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Mark Rothera, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F of Silence Therapeutics plc; 2. Based on my knowledge, this report does not contain any untrue statement of a materi |
|
| April 29, 2021 |
Silence Therapeutics Announces First Patient Dosed in GEMINI II Phase I Clinical Trial for SLN124 Exhibit 99.1 Silence Therapeutics Announces First Patient Dosed in GEMINI II Phase I Clinical Trial for SLN124 ? First patient dosed in study evaluating Silence?s wholly owned lead product candidate for thalassemia and myelodysplastic syndrome (MDS) 29 April 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (?Silence? or ?the Company?), a leader in the discovery, development and deliv |
|
| April 29, 2021 |
Section 1350 Certification of Chief Executive Officer Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Mark Rothera, President and Chief Executive Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Amendment No. 1 to |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| April 29, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| April 29, 2021 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Exhibit 12.2 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F of Silence Therapeutics plc; 2. Based on my knowledge, this report does not contain any untrue statement of a materi |
|
| April 29, 2021 |
Section 1350 Certification of Chief Financial Officer Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, Chief Financial Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Amendment No. 1 to the Annual Re |
|
| April 28, 2021 |
EX-99.1 2 sln-ex9916.htm EX-99.1 Exhibit 99.1 Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases 28 April 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for |
|
| April 28, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| April 19, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| April 19, 2021 |
Purchase of American Depositary Shares and PDMR Dealings EX-99.1 2 sln-ex9916.htm EX-99.1 Exhibit 99.1 Purchase of American Depositary Shares and PDMR Dealings 19th April 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today ann |
|
| April 12, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-248203 PROSPECTUS 49,106,988 Ordinary Shares Represented by 16,368,996 American Depositary Shares SILENCE THERAPEUTICS PLC Our American Depositary Shares, or ADSs, each representing three ordinary shares of Silence Therapeutics plc, are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol ?SLN?. The ADSs began trad |
|
| April 12, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration Statement No. 333-254021 PROSPECTUS 6,066,654 Ordinary Shares Represented by 2,022,218 American Depositary Shares SILENCE THERAPEUTICS PLC This prospectus relates to the resale from time to time in one or more offerings by the selling shareholders named herein of up to an aggregate of 6,066,654 of our ordinary shares, nominal value ?0 |
|
| April 8, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 8, 2021 Registration No. |
|
| April 8, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 8, 2021 Registration No. |
|
| March 30, 2021 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Exhibit 12.1 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Mark Rothera, certify that: 1. I have reviewed this annual report on Form 20-F of Silence Therapeutics plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to stat |
|
| March 30, 2021 |
Section 1350 Certification of Chief Financial Officer Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, Chief Financial Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on Form 20-F of th |
|
| March 30, 2021 |
Description of American Depositary Shares Exhibit 2.4 DESCRIPTION OF AMERICAN DEPOSITARY SHARES American Depositary Shares The Bank of New York Mellon, as depositary, will register and deliver American Depositary Shares, or ADSs. Each ADS will represent three ordinary shares (or a right to receive three ordinary shares) deposited with The Bank of New York Mellon, acting through an office located in England, as custodian. Each ADS will als |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 30, 2021 |
EX-99.1 2 sln-ex9916.htm EX-99.1 Exhibit 99.1 Silence Therapeutics Reports Full-year 2020 Results Advancing clinical programmes; On-track for three phase 1 data readouts in 2021 30 March 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics fo |
|
| March 30, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of princi |
|
| March 30, 2021 |
Description of Share Capital and Articles of Association EX-2.3 2 sln-ex23100.htm EX-2.3 Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, or the Articles, and relevant provisions of the U.K. Companies Act, or the Companies Act. The summary below contains only material informat |
|
| March 30, 2021 |
Section 1350 Certification of Chief Executive Officer Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Mark Rothera, President and Chief Executive Officer of Silence Therapeutics plc (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 1. The Annual Report on F |
|
| March 30, 2021 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Exhibit 12.2 CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Craig Tooman, certify that: 1. I have reviewed this annual report on Form 20-F of Silence Therapeutics plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to stat |
|
| March 15, 2021 |
Filed pursuant to Rule 424(b)(7) Registration Statement No. 333-254021 PROSPECTUS 6,066,654 Ordinary Shares Represented by 2,022,218 American Depositary Shares SILENCE THERAPEUTICS PLC This prospectus relates to the resale from time to time in one or more offerings by the selling shareholders named herein of up to an aggregate of 6,066,654 of our ordinary shares, nominal value ?0.05 per share, rep |
|
| March 11, 2021 |
March 11, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn:Ada Sarmento Re:Silence Therapeutics plc Registration Statement on Form F-1 Filed March 11, 2021 File No. 333-254021 Acceleration Request Requested Date: March 12, 2021 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 46 |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 9, 2021 |
As filed with the Securities and Exchange Commission on March 8, 2021 Registration No. |
|
| March 9, 2021 |
Exhibit 4.1 SILENCE THERAPEUTICS PLC AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement September 4, 2020 TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1 SECTION 1.1. American Depositary Shares 1 SECTION 1.2. CREST 2 SECTION 1.3. Commission 2 SECTION 1.4. Company 2 SECTION 1.5. Custodian 2 SECTION 1.6. Deliver; Surrender 2 SECTION 1.7. D |
|
| February 26, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2021 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of pri |
|
| February 26, 2021 |
EX-99.1 2 sln-ex9916.htm EX-99.1 EXHIBIT 99.1 Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases – Silence to receive $2 million research milestone payment – Silence is also eligible to receive up to $2 billion in total milestone payments across all three targets and tiered double-digit royalties on ne |
